# Safety and Efficacy of HO/02/02 20µg vs. SoC (Aloe Vera) to Reduce Radiation Dermatitis

> **NCT01923220** · EARLY_PHASE1 · UNKNOWN · sponsor: **HealOr** · enrollment: 90 (estimated)

## Conditions studied

- Breast Cancer

## Interventions

- **DRUG:** HO/02/02 20µg
- **OTHER:** Aloe Vera Jel

## Key facts

- **NCT ID:** NCT01923220
- **Lead sponsor:** HealOr
- **Sponsor class:** INDUSTRY
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2013-09
- **Primary completion:** 2014-09
- **Final completion:** 2014-12
- **Target enrollment:** 90 (ESTIMATED)
- **Last updated:** 2013-08-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01923220

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01923220, "Safety and Efficacy of HO/02/02 20µg vs. SoC (Aloe Vera) to Reduce Radiation Dermatitis". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01923220. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*